Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants

Mary Lou Clements-Mann, Robert A Dudas, Yasutaka Hoshino, Pamela Nehring, Ellen Sperber, Mariam Wagner, Ina Stephens, Ruth A Karron, Adamadie Deforest, Albert Z. Kapikian

Research output: Contribution to journalArticle


The safety and immunogenicity of an orally administered, live rotavirus vaccine comprised of four strains, each with a titer of 105.3 or 105.8 pfu, and each having 10 genes from the UK bovine strain and the VP7 gene from human rotavirus serotype 1, 2, 3, or 4, were evaluated in adults, young children and infants in randomized, double-blind phase 1 trials. Three doses of rotavirus vaccine or placebo given with childhood immunizations to infants at 2, 4, and 6 months of age were well tolerated and did not inhibit antibody responses to childhood vaccines which included DTP, Hib, hepatitis B and OPV. Serum rotavirus antibody responses were detected in 12 of 20 infants after 1 dose, and in 19/19 of the vaccinees after three doses. Neutralizing antibody responses were detected more often against the bovine rotavirus UK strain (95%) than to human rotavirus VP7 serotypes 1 (37%), 2 (32%), 3 (32%) or 4 (32%). The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further.

Original languageEnglish (US)
Pages (from-to)4676-4684
Number of pages9
Issue number32
Publication statusPublished - Sep 14 2001



  • Diarrheal vaccine
  • Human-bovine reassortant rotavirus vaccine
  • Live attenuated virus vaccine
  • Pediatric vaccine
  • Rotavirus antibody
  • Rotavirus immune responses
  • Rotavirus vaccine
  • Rotavirus vaccine immunity

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this